Pfizer and biontech achieve first authorization in the world for a vaccine to combat covid-19

New york and mainz, germany, december 2, 2020 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today that the medicines & healthcare products regulatory agency (mhra) in the u.k. has granted a temporary authorization for emergency use for their covid-19 mrna vaccine (bnt162b2), against covid-19. this constitutes the first emergency use authorization following a worldwide phase 3 trial of a vaccine to help fight the pandemic. pfizer and biontech are anticipating further regulatory decisions across the globe in the coming days and weeks and are ready to deliver vaccine doses following potential regulatory authorizations or approvals. the distribution of the vaccine in the u.k. will be prioritized according to the populations identified in guidance from the joint committee on vaccination and immunisation (jcvi).
BNTX Ratings Summary
BNTX Quant Ranking